Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: January 7, 2005
Last updated: July 9, 2013
Last verified: May 2005
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2006
  Estimated Primary Completion Date: No date given